Drugs are approved and available faster in US than most of EU, data shownews2024-12-11T18:30:47+00:00December 11th, 2024|Endpoints News|
Candel soars on prostate cancer data despite unclear prospectsnews2024-12-11T18:04:23+00:00December 11th, 2024|Endpoints News|
Eli Lilly has tapped telehealth startup Ro to distribute its single-dose Zepbound vialsnews2024-12-11T13:36:39+00:00December 11th, 2024|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
NewAmsterdam hits primary endpoint in CETP inhibitor trialnews2024-12-10T19:52:53+00:00December 10th, 2024|Endpoints News|
UniQure stock doubles after FDA meeting on Huntington’s diseasenews2024-12-10T19:39:13+00:00December 10th, 2024|Endpoints News|
#ASH24: J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of 10’ patientsnews2024-12-10T16:33:25+00:00December 10th, 2024|Endpoints News|
Roche initially didn’t want to buy Poseida — and partner Astellas didn’t submit an offer, new filings shownews2024-12-10T14:24:56+00:00December 10th, 2024|Endpoints News|
#ASH24: BTK drugs from AstraZeneca, Lilly and BeiGene take center stage in CLLnews2024-12-10T02:59:46+00:00December 10th, 2024|Endpoints News|
#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myelomanews2024-12-10T02:28:02+00:00December 10th, 2024|Endpoints News|
